A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule-Drug, Antibody-Drug, and Peptide-Drug Conjugates

被引：11

作者：

Zana, Aureliano ^{[1
]}

Puig-Moreno, Claudia ^{[1
,2
]}

Bocci, Matilde ^{[1
]}

Gilardoni, Ettore ^{[1
]}

Di Nitto, Cesare ^{[1
]}

Principi, Lucrezia ^{[1
]}

Ravazza, Domenico ^{[1
]}

Rotta, Giulia ^{[1
]}

Prodi, Eleonora ^{[1
]}

De Luca, Roberto ^{[1
]}

Neri, Dario ^{[1
,2
,3
]}

Cazzamalli, Samuele ^{[1
]}

机构：

[1] R&D Dept, Philochem AG, CH-8112 Zurich, Switzerland

[2] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland

[3] Philogen SpA, I-53100 Siena, Italy

来源：

BIOCONJUGATE CHEMISTRY | 2023年 / 34卷 / 07期

关键词：

Compendex;

D O I：

10.1021/acs.bioconjchem.3c00244

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Wepresent the first in vivo comparative evaluationof chemically defined antibody-drug conjugates (ADCs), smallmolecule-drug conjugates (SMDCs), and peptide-drug conjugates(PDCs) targeting and activated by fibroblast activation protein (FAP)in solid tumors. Both the SMDC (OncoFAP-Gly-Pro-MMAE) and the ADC(7NP2-Gly-Pro-MMAE) candidates delivered high amounts of active payload(i.e., MMAE) selectively at the tumor site, thus producing a potentantitumor activity in a preclinical cancer model.

引用

页码：1205 / 1211

页数：7

共 50 条

[21] Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Mo Wu
Wei Huang
Nan Yang
Yanyong Liu
Experimental Hematology & Oncology, 11
[22] Peptide-drug conjugates: A new paradigm for targeted cancer therapy
Wang, Mo
Liu, Jiawei
Xia, Mingjing
Yin, Libinghan
Zhang, Ling
Liu, Xifu
Cheng, Yu
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 265
[23] Peptide-drug conjugates as effective prodrug strategies for targeted delivery
Wang, Yin
Cheetham, Andrew G.
Angacian, Garren
Su, Hao
Xie, Lisi
Cui, Honggang
ADVANCED DRUG DELIVERY REVIEWS, 2017, 110 : 112 - 126
[24] Antibody-drug conjugates (ADCs) - New targeted therapies
Papakonstantinou G.
memo - Magazine of European Medical Oncology, 2013, 6 (4) : 223 - 224
[25] Trends in cancer-targeted antibody-drug conjugates
Bidard, Francois-Clement
Tredan, Olivier
TARGETED ONCOLOGY, 2014, 9 (01) : 1 - 8
[26] Antibody-drug conjugates: targeted delivery and future prospects
Lambert, John M.
THERAPEUTIC DELIVERY, 2016, 7 (05) : 279 - 282
[27] Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
Lindberg, Jakob
Nilvebrant, Johan
Nygren, Per-Ake
Lehmann, Fredrik
MOLECULES, 2021, 26 (19):
[28] Novel antibody-drug conjugates for selective tumor activation
Setter, Jocelyn R.
Doronina, Svetlana O.
Bovee, Tim D.
Anderson, Marti E.
Senter, Peter D.
Benjamin, Dennis R.
Lyon, Robert P.
CANCER RESEARCH, 2011, 71
[29] Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs)
Cooper, Bethany M.
Iegre, Jessica
O' Donovan, Daniel H.
Halvarsson, Maria Olwegard
Spring, David R.
CHEMICAL SOCIETY REVIEWS, 2021, 50 (03) : 1480 - 1494
[30] An FDA oncology analysis of antibody-drug conjugates
Saber, Haleh
Leighton, John K.
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2015, 71 (03) : 444 - 452

← 1 2 3 4 5 →